Cns Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.65next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly3MTarget: Sufficient to fund operations beyond 12 months following the $22.5M private placement
Quarterly Net Loss Quarterly-4.9MTarget: Minimize cash burn during strategic pivot
Watch Items
- In-licensing or acquisition of clinical-stage neurology and oncology assetsTrigger: Execution of definitive agreement for a new lead assetAction: Re-evaluate clinical development timeline, capital allocation, and cash runway
- Out-licensing of legacy glioblastoma programs (Berubicin and TPI-287)Trigger: Execution of out-licensing or partnership agreementsAction: Assess upfront payments, milestone structures, and royalty terms to offset historical cash burn
- Completion of the ongoing Phase 2 clinical trial of Berubicin in recurrent glioblastoma multiformeTrigger: Trial completion expected in July 2026Action: Review final clinical data and support potential out-licensing partners
Research as of 20 Jun 2026